IDH2 and central nervous system cancer: In view of the technical challenges of earlier studies and with the aim to develop a reliable, prospective, technically feasible, fast and affordable approach to discriminate IDH wild type and IDH mutated gliomas in vivo, we aimed here to process 18F-FET PET-guided routine 1H-MRS data from a standard 3T-MR scanner in a fully automatic manner to reveal IDH mutations with high accuracy.